The sale is a routine tax-withholding transaction tied to equity vesting. No material insider sentiment signal; monitor for any larger unplanned sales in future Form 4 filings.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $2.30entry
- T+1 · 20h ago −6.09%α −4.18% · $2.16
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Officer Martin Wilson filed Form 144 notice to sell 4,087 shares of Rocket Pharmaceuticals, valued at approximately $9,197, with the sale intended to cover a tax obligation from a vested equity award distribution. The amount is trivial relative to the company's $272M market cap and Wilson's recent trading history, making this a routine administrative filing.
Key Facts
- Wilson Martin, an officer of Rocket Pharmaceuticals, filed Form 144 on 2026-11-13 to sell 4,087 shares of common stock.
- The proposed sale value is $9,196.98, based on an estimated price of $2.25 per share.
- The filing states the sale is to cover a tax obligation from the settlement of a vested equity award distribution.
- Wilson Martin has sold 133,877 shares in four transactions since August 2026, totaling approximately $398,238.
- The company's market cap is $272M, making this proposed sale about 0.003% of market cap.
Financial Impact
Proposed sale of 4,087 shares worth ~$9,197, less than 0.004% of market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur or may differ in size.
- The officer has sold over 130K shares since August 2026, which could indicate ongoing portfolio diversification rather than a negative view.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-008008 |
| Document: 0001959173-26-008008-index.html | 0001959173-26-008008 |
| Document: 0001959173-26-008008.txt | 0001959173-26-008008 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers